Q32 Bio opened lower at $9.15, compared with its previous close of $9.20. In the last trading session, the stock traded between $8.53 and $9.23. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in Q32 Bio is now worth
$ 52.94
Resulting in a loss of
$ 47.06 (47.06%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.39 (-4.18%)
Day High
$9.23
Day Low
$8.53
Day Open
$9.15
Prev Close
$9.20
Volume
2,85,636
1W Return
-1.29%
1M Return
0.85%
3M Return
-42.85%
6M Return
70.17%
1Y Return
249.80%
Fundamentals
Market Cap ($ Mn)
264
PE Ratio
4.77
PB Ratio
3.36
PEG Ratio
-
ROE
1,147.67%
ROCE
49.17%
EPS (TTM)
-
Investment Returns
1 Week
-1.29%
1 Month
0.85%
3 Months
-42.85%
6 Months
70.17%
9 Months
150.43%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
53.7
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
18Jul
Q32 Bio files prospectus for offer and resale of 6.875M shares
Q32 Bio filed a prospectus for an offer and resale of 6.875 million shares by selling stockholders. The filing outlines the terms of the proposed transaction.
3mo ago
16Jul
Q32 Bio prices $200M public offering, shares fall
Q32 Bio Inc. priced a $200M public offering of common stock and pre-funded warrants to fund clinical development. Shares fell 7.42% following the announcement.
4mo ago
15Jul
Q32 Bio delivers 23.91% average annual return over five years
Q32 Bio reported an average annual return of 23.91% over the last five years, surpassing the market by 11.82% annually. With a current market cap of $317.42 million, a $100 stake from five years ago is now worth $287.54.
4mo ago
14Jul
Wells Fargo upgrades Q32 Bio to Overweight, sets $66 target
Wells Fargo analyst Derek Archila upgraded Q32 Bio from Equal-Weight to Overweight with a $66 price target. Separately, Oppenheimer analyst Jay Olson maintained an Outperform rating and raised the price target from $20 to $40.
4mo ago
13Jul
Q32 Bio reports positive bempikibart trial data in alopecia areata
Q32 Bio Inc. announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe alopecia areata. The data demonstrated a mean percent reduction in SALT score from baseline of 35.3% in the prespecified modified intent-to-treat (mITT) analysis. The company intends to advance the drug into a registration-directed program in the first half of 2027.
4mo ago
26Jun
Q32 Bio files prospectus for $300M offering
Q32 Bio has filed a prospectus with the SEC for a $300M offering. The filing details the terms and structure of the proposed securities sale.
